{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:08:46Z","timestamp":1792325326262,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008721.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000}}],"reference-count":251,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008721.pub3","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T13:49:17Z","timestamp":1679320157000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Anti-vascular endothelial growth factor for proliferative diabetic retinopathy"],"prefix":"10.1002","volume":"2023","author":[{"given":"Maria Jos\u00e9","family":"Martinez-Zapata","sequence":"additional","affiliation":[{"name":"Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Salvador","sequence":"additional","affiliation":[{"name":"Hospital de Sant Pau; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo J","family":"Mart\u00ed-Carvajal","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias de la Salud Eugenio Espejo; Universidad UTE (Cochrane Ecuador); Quito Ecuador"},{"name":"Universidad Francisco de Vitoria; Facultad de Medicina Cochrane Madrid; Madrid Spain"},{"name":"C\u00e1tedra Rectoral de Medicina Basada en la Evidencia; Universidad de Carabobo; Valencia Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 I","family":"Pijoan","sequence":"additional","affiliation":[{"name":"Hospital Universitario Cruces; Barakaldo Spain"},{"name":"BioCruces-Bizkaia Research Institute; CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Barakaldo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A","family":"Cordero","sequence":"additional","affiliation":[{"name":"Blanquerna School of Health Sciences; Universitat Ramon Llull; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Ponomarev","sequence":"additional","affiliation":[{"name":"Interdepartmental Division of Critical Care Medicine; University of Toronto; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Kernohan","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Sol\u00e0","sequence":"additional","affiliation":[{"name":"Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA); University of Florence; Florence Italy"},{"name":"Centre for Public Health; Queen's University Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"issue":"3-4","key":"10.1002\/14651858.CD008721.pub3-BIB0001|cit1","first-page":"10","article-title":"Comparison between panretinal photocoagulation and panretinal photocoagulation plus intravitreal bevacizumab in proliferative diabetic retinopathy","volume":"24","author":"Ahmad","year":"2012","journal-title":"Journal of Ayub Medical College"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Ali W Abbasi KZ Raza A Panretinal photocoagulation plus intravitreal bevacizumab versus panretinal photocoagulation alone for proliferative diabetic retinopathy Journal of the College of Physicians and Surgeons Pakistan 2018 28 12 923-7","DOI":"10.29271\/jcpsp.2018.12.923"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/IAE.0000000000001673","article-title":"Efficacy of Intravitreal ranibizumab Injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy","volume":"38","author":"Chelala","year":"2018","journal-title":"Retina"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0004|cit4","unstructured":"Dirani A Fadlallah A Azar G Chelala E Nehme J Alameddine R Intravitreal ranibizumab for vitreous hemorrhage in proliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 2014 55 13 ARVO E abstract 4395"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamaophthalmol.2013.2015","article-title":"Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy","volume":"131","author":"Bhavsar","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/jamaophthalmol.2014.287","article-title":"Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy","volume":"132","author":"Bhavsar","year":"2014","journal-title":"JAMA Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0007|cit7","first-page":"467","article-title":"Correction: Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial (JAMA Ophthalmology (2018) 136:10 (1138-48) DOI: 10.1001\/jamaophthalmol.2018.3255)","volume":"137","year":"2019","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2016.08.008","article-title":"Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: Patient-centered outcomes from a randomized clinical trial","volume":"170","author":"Beaulieu","year":"2016","journal-title":"American Journal Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2016.08.008","article-title":"Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: Patient-centered outcomes from a randomized clinical trial","volume":"170","author":"Beaulieu","year":"2016","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/IAE.0000000000002633","article-title":"Anti-vascular endothelial growth factor therapy and risk of traction retinal detachment in eyes with proliferative diabetic retinopathy: pooled analysis of five DRCR retina network randomized clinical trials","volume":"40","author":"Bressler","year":"2020","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2016.12.005","article-title":"Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab","volume":"124","author":"Bressler","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Bressler SB Beaulieu WT Glassman AR Gross JG Melia M Chen E Photocoagulation versus ranibizumab for proliferative diabetic retinopathy: should baseline characteristics affect choice of treatment? Retina 2019 39 9 1646-54","DOI":"10.1097\/IAE.0000000000002377"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jama.2019.0374","article-title":"Errors in analysis of mean deviations in study of photocoagulation vs ranibizumab for diabetic retinopathy","volume":"321","author":"Glassman","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaophthalmol.2017.0969","article-title":"Interim safety data comparing ranibizumab with panretinal photocoagulation among participants with proliferative diabetic retinopathy","volume":"135","author":"Gross","year":"2017","journal-title":"JAMA Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1138-48","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jamaophthalmol.2017.0837","article-title":"Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy: secondary analysis from a diabetic retinopathy clinical research network randomized clinical trial","volume":"135","author":"Hutton","year":"2017","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Jampol LM Odia I Glassman AR Baker CW Bhorade M Han DP Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: comparison of peripapillary retinal nerve fiber layer thickness in a randomized clinical trial Retina 2019 39 1 69 78","DOI":"10.1097\/IAE.0000000000001909"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0018|cit18","first-page":"944","article-title":"Erratum: Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial (JAMA - Journal of the American Medical Association (2015) 314:20 (2137-2146))","volume":"315","author":"Ross","year":"2016","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Sun JK Glassman AR Beaulieu WT Stockdale CR Bressler NM Flaxel C Rationale and application of the Protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy Ophthalmology 2019 126 1 87 95","DOI":"10.1016\/j.ophtha.2018.08.001"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0020|cit20","unstructured":"Sun JK Clinically relevant outcomes from the DRCR.net anti-VEGF treatment algorithm for proliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 2018 59 9 ARVO E abstract 735"},{"issue":"20","key":"10.1002\/14651858.CD008721.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0022|cit22","first-page":"273","article-title":"Comparison of panretinal photocoagulation (PRP) with PRP plus intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy","volume":"17","author":"Ergur","year":"2009","journal-title":"Retina-Vitreus"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000442026","article-title":"Ranibizumab for high-risk proliferative diabetic retinopathy: an exploratory randomized controlled trial","volume":"235","author":"Figueira","year":"2016","journal-title":"Ophthalmologica"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"691-700","DOI":"10.1016\/j.ophtha.2017.12.008","article-title":"Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study)","volume":"125","author":"Figueira","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0025|cit25","first-page":"4","article-title":"Ranibizumab 0.5 mg combined with panretinal photocoagulation versus panretinal photocoagulation monotherapy in high-risk proliferative diabetic retinopathy patients: 12-month proteus results","volume":"58","author":"Figueira","year":"2017","journal-title":"Ophthalmic Research"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/bjo.2008.155663","article-title":"Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy","volume":"93","author":"Gonz\u00e1lez","year":"2009","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0027|cit27","unstructured":"Gonzalez VH Vann VR Banda-Gonzales RM Selective VEGF Inhibition: effectiveness in modifying the progression of proliferative diabetic retinopathy American Academy of Ophthalmology 2006 279"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0028|cit28","unstructured":"Gonzalez VH Vann VR Banda RM Giuliari GP Guel DA Pegaptanib sodium (Macugen\u00ae) versus panretinal photocoagulation (PRP) for the regression of proliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 2007 48 ARVO E abstract 4030"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0029|cit29","unstructured":"Gonzalez VH Vann VR Treatment of proliferative diabetic retinopathy with intravitreal pegaptanib vs. panretinal photocoagulation American Academy of Ophthalmology 2007 265"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0030|cit30","unstructured":"Gonzalez VH Variable dosing of anti-VEGF therapy in the management of proliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 55 13 ARVO E abstract 4410"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"He F Yang J Zhang X Yu W Efficacy of conbercept combined with panretinal photocoagulation in the treatment of proliferative diabetic retinopathy Scientific Reports 2020 10 1 8778","DOI":"10.1038\/s41598-020-65833-0"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0032|cit32","unstructured":"Lang GE Stahl A Voegeler J Quiering C Lorenz K Spital G Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy- the PRIDE study Acta Ophthalmologica 10.1111\/aos.14312"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0033|cit33","unstructured":"Lorenz K Lang GE Stahl A Quiering C Sander L Spital G Influence of ranibizumab, laser photocoagulation or combination therapy on high-risk proliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 2019 60 9 ARVO E abstract 2789"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0034|cit34","unstructured":"Stahl A Liakopoulos S Lorenz K Quiering C Sander L Spital G Retreatment needs of patients with proliferative diabetic retinopathy treated with ranibizumab, laser or combination therapy Investigative Ophthalmology and Visual Science 2019 60 9 ARVO E abstract 1734"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"00211","DOI":"10.15406\/aovs.2017.07.00211","article-title":"Panretinal photocoagulation versus Intravitreal bevacizumab for proliferative diabetic retinopathy treatment","volume":"7","author":"Marashi","year":"2017","journal-title":"Advances in Ophthalmology and Visual System"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0036|cit36","first-page":"972","article-title":"Effect of intravitreal injection of Bevacizumab for vitreous hemorrhage in patients with proliferative diabetic retinopathy","volume":"16","author":"Meng","year":"2016","journal-title":"International Eye Science"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/112067210801800215","article-title":"Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial","volume":"18","author":"Mirshahi","year":"2008","journal-title":"European Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000348605","article-title":"Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial","volume":"230","author":"Preti","year":"2013","journal-title":"Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/bjophthalmol-2012-302675","article-title":"Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial","volume":"97","author":"Preti","year":"2013","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Preti RC Mutti A Ferraz DA Zacharias LC Nakashima Y Takahashi WY The effect of laser pan-retinal photocoagulation with or without intravitreal bevacizumab injections on the OCT-measured macular choroidal thickness of eyes with proliferative diabetic retinopathy Clinics 2017 72 2 81 6","DOI":"10.6061\/clinics\/2017(02)03"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1590\/S0004-27492013000100006","article-title":"Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy","volume":"76","author":"Araujo Lucena","year":"2013","journal-title":"Arquivos brasileiros de oftalmologia"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1590\/S0004-27492013000100006","article-title":"Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy","volume":"76","author":"Lucena","year":"2013","journal-title":"Arquivos Brasileiros de Oftalmologia"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10633-012-9322-5","article-title":"Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy","volume":"124","author":"Messias","year":"2012","journal-title":"Documenta Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy","volume":"89","author":"Ramos Filho","year":"2011","journal-title":"Acta Ophthalmologica"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Shaikh FF Jatoi SM Comparison of efficacy of combination therapy of an intravitreal injection of bevacizumab and photocoagulation versus pan retinal photocoagulation alone in high risk proliferative diabetic retinopathy Pakistan Journal of Medical Sciences 2021 37 1 1 5","DOI":"10.12669\/pjms.37.1.3141"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1097\/IAE.0000000000001027","article-title":"Choroidal thickness changes in proliferative diabetic retinopathy treated with panretinal photocoagulation versus panretinal photocoagulation with intravitreal bevacizumab","volume":"36","author":"Roohipoor","year":"2016","journal-title":"Retina"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Roohipour R Sharifian E Moghimi S Aghsaei Fard M Ghassemi F Zarei M The effect of panretinal photocoagulation (PRP) versus intravitreal bevacizumab (IVB) plus prp on peripapillary retinal nerve fiber layer (RNFL) thickness analyzed by optical coherence tomography in patients with proliferative diabetic retinopathy Journal of Ophthalmic and Vision Research 2019 14 2 157 63","DOI":"10.4103\/jovr.jovr_160_17"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.12669\/pjms.331.11497","article-title":"Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy","volume":"33","author":"Sameen","year":"2017","journal-title":"Pakistan Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0049|cit49","first-page":"244","article-title":"Panretinal photocoagulation versus intravitreal bevacizumab versus a proposed modified combination therapy for proliferative diabetic retinopathy treatment; a randomized 3-arm clinical trial","volume":"Suppl 1","author":"Ramezani","year":"2021","journal-title":"Ophthalmologica"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/IAE.0000000000003450","article-title":"Panretinal photocoagulation versus intravitreal bevacizumab versus a proposed modified combination therapy for treatment of proliferative diabetic retinopathy: A Randomized three-arm clinical trial (CTPDR Study)","volume":"42","author":"Shahraki","year":"2022","journal-title":"Retina"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"501\u20137","DOI":"10.1001\/jamaophthalmol.2021.0108","article-title":"Topographical response of retinal neovascularization to aflibercept or panretinal photocoagulation in proliferative diabetic retinopathy: post hoc analysis of the CLARITY randomized clinical trial","volume":"139","author":"Halim","year":"2021","journal-title":"JAMA Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10020358","article-title":"Low luminance visual acuity and low luminance deficit in proliferative diabetic retinopathy","volume":"10","author":"Karatsai","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1167\/iovs.17-23509","article-title":"Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy: CLARITY substudy","volume":"59","author":"Nicholson","year":"2018","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jamaophthalmol.2019.0440","article-title":"Retinal nonperfusion characteristics on ultra-widefield angiography in eyes with severe nonproliferative diabetic retinopathy and proliferative diabetic retinopathy","volume":"137","author":"Nicholson","year":"2019","journal-title":"JAMA Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"e008405","DOI":"10.1136\/bmjopen-2015-008405","article-title":"Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial","volume":"5","author":"Sivaprasad","year":"2015","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.ophtha.2009.07.001","article-title":"Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial","volume":"116","author":"Ahmadieh","year":"2009","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ophtha.2011.03.036","article-title":"The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy","volume":"118","author":"Ahn","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0059|cit59","unstructured":"Albuquerque TL Pierozzi GS Ara\u00fajo ACC Neto NH Carregal TB Martins MC Comparative, randomized, double blinded study of the use of Anti-VEGF in patients with vitreous hemorrhage or tractional retinal detachment secondary to diabetic retinopathy Investigative Ophthalmology and Visual Science 2014 55 13 ARVO E abstract 4391"},{"issue":"23","key":"10.1002\/14651858.CD008721.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1001\/jama.2020.23027","article-title":"Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial","volume":"324","author":"Antoszyk","year":"2020","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0061|cit61","unstructured":"Anti-VEGF vs. prompt vitrectomy for VH from PDR (AB) clinicaltrials.gov\/ct2\/show\/NCT02858076"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajo.2019.05.007","article-title":"Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: a prospective randomized clinical trial","volume":"207","author":"Arevalo","year":"2019","journal-title":"American Journal Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0063|cit63","unstructured":"Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group clinicaltrials.gov\/show\/NCT01976923 Accessed 28\/12\/2017"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ophtha.2008.12.024","article-title":"Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy","volume":"116","author":"Arimura","year":"2009","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0065|cit65","first-page":"526","article-title":"ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy","volume":"83","author":"Barroso","year":"2020","journal-title":"Arquivos Brasileiros de Oftalmologia"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0066|cit66","first-page":"613","article-title":"Effects of laser photocoagulation combined with anti-VEGF drugs at different time in the treatment of diabetic retinopathy","volume":"20","author":"Bi","year":"2020","journal-title":"International Eye Science"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.ophtha.2018.04.039","article-title":"Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: factors associated with vision and edema outcomes","volume":"125","author":"Bressler","year":"2018","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0068|cit68","first-page":"1443","article-title":"Effects of Conbercept combined with laser on inflammatory factors, oxidative stress levels and retinal hemodynamics in diabetic retinopathy","volume":"18","author":"Bu","year":"2018","journal-title":"International Eye Science"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2017.08.013","article-title":"Preoperative bevacizumab administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a randomized and controlled trial comparing interval variation","volume":"183","author":"Castillo","year":"2017","journal-title":"American Journal Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0070|cit70","unstructured":"Comparison of interval variation and dosage in preoperative bevacizumab and ziv-aflibercept administration in proliferative diabetic retinopathy undergoing vitrectomy clinicaltrials.gov\/ct2\/history\/NCT02590094"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00592-020-01548-y","article-title":"Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study","volume":"57","author":"Chatziralli","year":"2020","journal-title":"Acta Diabetologica"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcrs.2008.09.019","article-title":"Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study","volume":"35","author":"Cheema","year":"2009","journal-title":"Journal of Cataract and Refractive Surgery"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0073|cit73","first-page":"1178","article-title":"Effect of retinal photocoagulation combined with Conbercept on the levels of vascular endothelial growth factor and SDF-1 in aqueous humor of DR patients","volume":"19","author":"Chen","year":"2019","journal-title":"International Eye Science"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/bjo.2009.168997","article-title":"Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy","volume":"94","author":"Cho","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/IAE.0b013e31819a5fc2","article-title":"Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy","volume":"29","author":"Cho","year":"2009","journal-title":"Retina"},{"issue":"13","key":"10.1002\/14651858.CD008721.pub3-BIB0076|cit76","first-page":"2302","article-title":"A pilot randomized controlled trial of ranibizumab pre-treatment for diabetic vitrectomy (The RaDiVit study)","volume":"55","author":"Comyn","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1253\u201358","DOI":"10.1038\/eye.2017.75","article-title":"Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study)","volume":"31","author":"Comyn","year":"2017","journal-title":"Eye"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00417-010-1303-3","article-title":"Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy","volume":"248","author":"Di Lauro","year":"2010","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"e2731","DOI":"10.1097\/MD.0000000000002731","article-title":"Evaluation of intravitreal ranibizumab on the surgical outcome for diabetic retinopathy with tractional retinal detachment","volume":"95","author":"Dong","year":"2016","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0080|cit80","unstructured":"Dufour Q Matamoros E Boissonnot M Ingrand P Saleh M Leveziel N MEDICARE study. Study design and time before recurrence of retinal neovascularization after anti-VEGF injections Investigative Ophthalmology and Visual Science 2017 58 8 ARVO E abstract 5806"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0081|cit81","first-page":"709","article-title":"Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy","volume":"2","author":"El-Batarny","year":"2008","journal-title":"Clinical Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1111\/j.1755-3768.2011.02364.x","article-title":"Intravitreal bevacizumab versus panretinal photocoagulation for treatment-na\u00efve proliferative and severe nonproliferative diabetic retinopathy","volume":"90","author":"Ernst","year":"2012","journal-title":"Acta Ophthalmologica"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0083|cit83","unstructured":"Garcia-Aguirre G Reyna-Castel\u00e1n E Torres-Soriano M Kon-Jara V Quiroz-Mercado H Bevacizumab vs. panretinal photocoagulation for the treatment of proliferative and severe non-proliferative diabetic retinopathy: a contralateral eye study Investigative Ophthalmology and Visual Science 2008 49 13 ARVO E abstract 2750"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0084|cit84","unstructured":"Garcia-Aguirre G Reyna-Castelan E Torres M Kon-Jara V Quiroz-Mercado H Intravitreal bevacizumab vs. panretinal photocoagulation for the treatment of proliferative and severe non-proliferative diabetic retinopathy: a contralateral eye study Investigative Ophthalmology and Visual Science 2007 48 ARVO E abstract 5041"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1254\u201360","DOI":"10.1097\/IAE.0b013e31820a68e5","article-title":"Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage","volume":"31","author":"Farahvash","year":"2011","journal-title":"Retina"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0086|cit86","unstructured":"Ferraz DA Vasquez L Motta A Preti RC Sophie R Bittencourt MG Contrast sensitivity evaluation in high-risk treatment-naive proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal Ranibizumab Investigative Ophthalmology and Visual Science 2014 55 13 ARVO E abstract 4414"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/IAE.0000000000000363","article-title":"A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy","volume":"2","author":"Ferraz","year":"2015","journal-title":"Retina"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0088|cit88","first-page":"52","article-title":"Intravitreal bevacizumab and panretinal photocoagulation as combined treatment in proliferative diabetic retinopathy","volume":"18","author":"Fulda","year":"2010","journal-title":"Retina-Vitreus"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0089|cit89","unstructured":"Genovesi-Ebert F Rizzo S Di Bartolo E Miniaci S Vento A Palla M Injection of intravitreal Avastin before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 2007 48 13 ARVO E abstract 5044"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0090|cit90","unstructured":"Gonzalez VH Macugen Diabetic Retinopathy Study Group Pegaptanib in diabetic retinopathy: improvements in diabetic macular edema, retinal neovascularization, and diabetic retinopathy severity American Academy of Ophthalmology 2006 192"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1448\u201357","DOI":"10.1016\/j.ophtha.2019.08.010","article-title":"Panretinal photocoagulation for diabetic retinopathy in the RIDE and RISE Trials: not 1 and Done","volume":"128","author":"Gonzalez","year":"2021","journal-title":"Ophtalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0092|cit92","unstructured":"Hach JM Wykoff CC Babiuch A Figueiredo NAL Srivastava SK Longitudinal panretinal leakage Index assessment in proliferative diabetic retinopathy treated with intravitreal aflibercept on ultra-widefield fluorescein angiography from the RECOVERY study Investigative Ophthalmology and Visual Science 2019 60 9 ARVO E abstract 5337"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0093|cit93","unstructured":"Hach JM Wykoff CC Babiuch A Yu H Talcott K Srivastava SK The RECOVERY study 2-year assessment of longitudinal panretinal leakage index following intravitreal aflibercept for proliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 2020 61 7 ARVO E abstract 3327"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.oret.2022.02.013","article-title":"Final outcomes from the randomized RECOVERY trial of Aflibercept for retinal nonperfusion in proliferative diabetic retinopathy","volume":"6","author":"Wykoff","year":"2022","journal-title":"Ophthalmology Retina"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/IAE.0b013e3181c70168","article-title":"Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy","volume":"30","author":"Hattori","year":"2010","journal-title":"Retina"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0096|cit96","doi-asserted-by":"crossref","unstructured":"Hershberger V Ghanekar A Ranibizumab-induced diabetic retinopathy improvement-results from patients at high risk for vision loss in RIDE\/RISE and protocol S Diabetes 2018 A158","DOI":"10.2337\/db18-601-P"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0097|cit97","first-page":"281","article-title":"Clinical study on the treatment of PDR with cataract by vitreous cavity injection and intraocular lens implantation","volume":"17","author":"Hu","year":"2017","journal-title":"International Eye Science"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1097\/IAE.0b013e3181b094b7","article-title":"Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage","volume":"29","author":"Huang","year":"2009","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"130","author":"Ip","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1755-3768.2008.01353.x","article-title":"Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy","volume":"87","author":"Jiang","year":"2009","journal-title":"Acta Ophthalmologica"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","article-title":"Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)","volume":"26","author":"Jorge","year":"2006","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/IAE.0b013e31819c6302","article-title":"Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study","volume":"29","author":"Lanzagorta-Aresti","year":"2009","journal-title":"Retina"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/02713683.2013.867064","article-title":"Changes of choroidal thickness after treatment for diabetic retinopathy","volume":"7","author":"Lee","year":"2014","journal-title":"Current Eye Research"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0104|cit104","first-page":"1202","article-title":"Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab","volume":"8","author":"Li","year":"2015","journal-title":"International Journal Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12886-022-02303-3","article-title":"The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage","volume":"22","author":"Li","year":"2022","journal-title":"BMC Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0106|cit106","unstructured":"25-G vitrectomy with ranibizumab or triamcinolone acetonide on PDR in China-randomized clinical trial (aiRTo-PDR) clinicaltrials.gov\/ct2\/show\/NCT02447185"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"Article ID 2676","DOI":"10.5402\/2012\/267643","article-title":"Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy","volume":"2012","author":"L\u00f3pez-L\u00f3pez","year":"2012","journal-title":"ISRN Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0108|cit108","first-page":"111","article-title":"Clinical effect of intravitreal injection of Ranibizumab for severe proliferativediabetic retinopathy","volume":"16","author":"Ma","year":"2016","journal-title":"International Eye Science"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Maguire MG Liu D Glassman AR Jampol LM Johnson CA Baker CW Visual field changes over 5 years in patients treated with panretinal photocoagulation or ranibizumab for proliferative diabetic retinopathy JAMA Ophthalmology 2020 138 3 285 93","DOI":"10.1001\/jamaophthalmol.2019.5939"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/IAE.0000000000000577","article-title":"Randomized controlled study of intravitreal bevacizumab 0.16 mg injected one day before surgery for proliferative diabetic retinopathy","volume":"35","author":"Manabe","year":"2015","journal-title":"Retina"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0111|cit111","first-page":"ARVO E","article-title":"Randomized trial of intravitreous anti-VEGF for prevention of vision threatening complications of diabetic retinopathy (protocol W)","volume":"62","author":"Maturi","year":"2021","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008721.pub3-BIB0112|cit112","first-page":"S30","article-title":"Retinal function in proliferative diabetic retinopathy treated with intravitreal ranibizumab and laser photocoagulation targeted to ischemic retina","volume":"136","year":"2018","journal-title":"International Society for Clinical Electrophysiology of Vision"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008721.pub3-BIB0113|cit113","first-page":"S32","article-title":"The photopic hill in intravitreal ranibizumab and panretinal photocoagulation for proliferative diabetic retinopathy","volume":"139","year":"2019","journal-title":"Documenta Ophthalmologica"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0114|cit114","unstructured":"Messias A Katharina M De Montier Barroso R Jorge R The light-adapted full-field erg luminance-response series in proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation Investigative Ophthalmology and Visual Science 2019 60 9 ARVO E abstract 5954"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"121-9","DOI":"10.1007\/s10633-018-9655-9","article-title":"Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation","volume":"137","author":"Messias","year":"2018","journal-title":"Documenta Ophthalmologica"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1600-0420.2007.01042.x","article-title":"Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy","volume":"86","author":"Minnella","year":"2008","journal-title":"Acta Opthalmologica"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/112067210901900526","article-title":"Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy","volume":"19","author":"Modarres","year":"2009","journal-title":"European Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Modarres M Nazari H Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy American Academy of Ophthalmology 2007 199","DOI":"10.1016\/S0084-392X(08)70097-2"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0120|cit120","unstructured":"Noctura400 treatment for diabetic retinopathy: pilot study to demonstrate and evaluate the care pathway for National Health Service (NHS) adoption clinicaltrials.gov\/ct2\/history\/NCT02207712"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0121|cit121","unstructured":"Evaluation of treatment of high-risk proliferative diabetic retinopathy with intravitreal aflibercept injection (ELYSIAN) clinicaltrials.gov\/ct2\/show\/NCT02630277"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0122|cit122","unstructured":"Intravitreal injection of ranibizumab versus sham before vitrectomy in patients with proliferative diabetic retinopathy clinicaltrials.gov\/ct2\/show\/NCT02857491"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0123|cit123","unstructured":"Endolaserless vitrectomy with Intravitreal IAI for PDR-Related VH (LASERLESS) clinicaltrials.gov\/ct2\/show\/NCT02976012"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0124|cit124","unstructured":"Multicenter clinical study of anti-VEGF treatment on high risk Diabetic Retinopathy (DR) clinicaltrials.gov\/ct2\/show\/NCT03452657"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0125|cit125","unstructured":"ETDRS PRP with IVR versus retinal photocoagulation targeted to ischemic retina With IVR for the treatment of PDR clinicaltrials.gov\/ct2\/show\/NCT03904056"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0126|cit126","unstructured":"Long-term efficacy and safety of intravitreal aflibercept injections for the treatment of diabetic retinopathy for subjects who completed the 2-year PANORAMA trial clinicaltrials.gov\/ct2\/show\/NCT04708145"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0127|cit127","unstructured":"Evaluation of RC28-E injection in diabetic retinopathy clinicaltrials.gov\/ct2\/show\/NCT04782128"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0128|cit128","unstructured":"Oh J Kim S Kim K Panretinal photocoagulation(PRP) versus Intravitreal bevacizumab plus PRP for diabetic retinopathy Investigative Ophthalmology and Visual Science 2014 55 13 ARVO E abstract 3900"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Parikakis E Laser or Anti-VEGF for proliferative diabetic retinopathy Acta Ophalmologica 2018 96 S261 94","DOI":"10.1111\/aos.13972_351"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00417-008-0774-y","article-title":"Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)","volume":"246","author":"Rizzo","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/IAE.0b013e31815e9385","article-title":"Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema","volume":"28","author":"Scott","year":"2008","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3341\/kjo.2009.23.4.266","article-title":"Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy","volume":"23","author":"Shin","year":"2009","journal-title":"Korean Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/archophthalmol.2012.1611","article-title":"Angiofibrotic response to vascular endothelial growth factor Inhibition in diabetic retinal detachment","volume":"130","author":"Sohn","year":"2012","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0134|cit134","unstructured":"Prevention of macular edema In patients with diabetic retinopathy undergoing cataract surgery clinicaltrials.gov\/show\/NCT01988246"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3928\/23258160-20200228-06","article-title":"Prevention of macular edema in patients with diabetic retinopathy undergoing cataract surgery: The PROMISE trial","volume":"51","author":"Song","year":"2020","journal-title":"Ophthalmic Surgery, Lasers and Imaging Retina"},{"issue":"13","key":"10.1002\/14651858.CD008721.pub3-BIB0136|cit136","first-page":"ARVO E","article-title":"Varying doses of intravitreal bevacizumab (Avastin) for the treatment of proliferative diabetic retinopathy","volume":"48","author":"Stergiou","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/IAE.0000000000000900","article-title":"Intravitreal conbercept (kh902) for surgical treatment of severe proliferative diabetic retinopathy","volume":"35","author":"Su","year":"2016","journal-title":"Retina"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0138|cit138","first-page":"1772","article-title":"Study of anti-vascular endothelial growth factor medicine for proliferative diabetic retinopathy at perioperative period","volume":"15","author":"Sun","year":"2015","journal-title":"International Eye Science"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1600-0420.2007.01056.x","article-title":"Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)","volume":"86","author":"Tonello","year":"2008","journal-title":"Acta Ophthalmologica"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10633-021-09848-6","article-title":"Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas-A randomized study","volume":"143","author":"Toscano","year":"2021","journal-title":"Documenta Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0141|cit141","first-page":"1257","article-title":"Clinical effect of vitrectomy with intravitreal ranibizumab for diabetic retinopathy","volume":"14","author":"Wang","year":"2014","journal-title":"International Eye Science"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0142|cit142","first-page":"5969","article-title":"Therapeutic effects of anti-VEGF drugs, combined with laser therapy, on diabetic retinopathy and its effects on choroid thickness","volume":"12","author":"Wang","year":"2019","journal-title":"International Journal of Clinical and Experimental Medicine"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0143|cit143","unstructured":"Intravitreal aflibercept for retinal non-perfusion in proliferative diabetic retinopathy (RECOVERY) clinicaltrials.gov\/ct2\/show\/NCT02863354"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0144|cit144","unstructured":"Nittala MG Alagorie AR Velaga SB Zhou B Rusakevich AM Wykoff CC Effect of intravitreal aflibercept on diabetic retinopathy severity and visual function in subjects with proliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 2020 61 7 ARVO E abstract 5280"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0145|cit145","unstructured":"Nittala MG Fan W Velaga SB Lampen S Ip MS Wykoff CC Effect of intravitreal aflibercept on optical coherence tomography angiography vessel density in subjects with proliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 2018 59 9 ARVO E abstract 1914"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0146|cit146","unstructured":"Nittala MG Fan W Velaga SB Zhou B Lampen S Rusakevich AM Intravitreal aflibercept for retinal non- perfusion in proliferative diabetic retinopathy: primary outcomes from the RECOVERY study Investigative Ophthalmology and Visual Science 2019 60 9 ARVO E abstract 6547"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0147|cit147","doi-asserted-by":"crossref","unstructured":"Wykoff CC Nittala MG Zhou B Fan W Velaga SB Lampen SIR Intravitreal aflibercept for retinal nonperfusion in proliferative diabetic retinopathy: outcomes from the randomized RECOVERY trial Ophthalmologica Retina 2019 3 12 1076 86","DOI":"10.1016\/j.oret.2019.07.011"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"Article ID 2473","DOI":"10.1155\/2016\/2473234","article-title":"A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy","volume":"2016","author":"Yang","year":"2016","journal-title":"Journal Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/IAE.0b013e3181a3b7ef","article-title":"Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy","volume":"29","author":"Yeh","year":"2009","journal-title":"Retina"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0150|cit150","first-page":"1402","article-title":"Effect of vitrectomy combined medication hyperplastic on patients with diabetic retinopathy","volume":"45","author":"Yu","year":"2015","journal-title":"Guoji Yanke Zazhi"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0151|cit151","doi-asserted-by":"crossref","unstructured":"Yu HJ Ehlers JP Sevgi DD Hach J O'Connell M Real-time photographic and fluorescein angiographic-guided management of diabetic retinopathy: randomized prime trial outcomes Investigative Ophthalmology and Visual Science 2021 62 ARVO E abstract 1099","DOI":"10.1016\/j.ajo.2021.01.024"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"590","DOI":"10.12669\/pjms.292.3044","article-title":"Intravitreal Avastin as an adjunct in patients with proliferative retinopathy undergoing pars plana vitrectomy","volume":"29","author":"Zaman","year":"2013","journal-title":"Pakistan Journal of Medical Sciences"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000495423","article-title":"Single-dose intravitreal conbercept before panretinal photocoagulation as an effective adjunctive treatment in Chinese proliferative diabetic retinopathy","volume":"242","author":"Zhang","year":"2019","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0154|cit154","first-page":"475","article-title":"Avastin combined with vitreous cavity injection of triamcinolone acetonide in treatment of diabetic retinopathy with macular edema","volume":"10","author":"Zhou","year":"2010","journal-title":"International Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0155|cit155","unstructured":"Zhou WX Liu ZY Prognosis of VEGF inhibitors combined with laser therapy in patients with diabetic retinopathy International Eye Science 2017 12 234 37"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0156|cit156","unstructured":"Study on the treatment mode of stage IV diabetic retinopathy www.chictr.org.cn\/searchprojen.aspx 2017"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0157|cit157","unstructured":"Conbercept vs panretinal photocoagulation for the management of proliferative diabetic retinopathy clinicaltrials.gov\/ct2\/show\/NCT02911311"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0158|cit158","unstructured":"Study of efficacy and safety of brolucizumab versus panretinal photocoagulation laser in patients with proliferative diabetic retinopathy clinicaltrials.gov\/ct2\/show\/NCT04278417 2020 (first received 20 February 2020)"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0159|cit159","first-page":"84","article-title":"Retinopathy in diabetes","volume":"27 Suppl 1","author":"Fong","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","article-title":"Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals","volume":"113","author":"Adamis","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0161|cit161","unstructured":"Aluko P Graybill E Craig D Henderson C Drummond M Wilson EC on behalf of the Campbell and Cochrane Economics Methods Group Chapter 20: Economic evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","article-title":"Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up","volume":"114","author":"Arevalo","year":"2007","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology."},{"key":"10.1002\/14651858.CD008721.pub3-BIB0166|cit166","unstructured":"Brown DM Emanuelli A Bandello F Barranco JJE Figueira J Souied E Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies Investigative Ophthalmology and Visual Science 2021 62 8 ARVO E abstract 1045"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0002-9440(10)61775-0","article-title":"Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide","volume":"159","author":"Bussolati","year":"2001","journal-title":"American Journal of Pathology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2796.2003.01297.x","article-title":"Manipulating angiogenesis in medicine","volume":"255","author":"Carmeliet","year":"2004","journal-title":"Journal of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","article-title":"Modeling good research practices - overview: a report of the ISPOR-SMDM modeling good research practices task force - 1. Medical Decision Making","volume":"32","author":"Caro","year":"2012","journal-title":"Medical Decision Making"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/01.iae.0000225351.87205.69","article-title":"Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy","volume":"26","author":"Chen","year":"2006","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archopht.1996.01100140281004","article-title":"Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22","volume":"114","author":"Chew","year":"1996","journal-title":"Archives of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2006.04.033","article-title":"A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema","volume":"113","author":"Chun","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0174|cit174","unstructured":"Covidence Veritas Health Innovation"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Adamis","year":"2005","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0176|cit176","first-page":"233","article-title":"Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18","volume":"39","author":"Davis","year":"1998","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0161-6420(78)35693-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings","volume":"85","year":"1978","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000395330","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy Study report no. 5","volume":"2","year":"1981","journal-title":"Developments in Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0180|cit180","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. The Diabetic Retinopathy Study Research Group","volume":"88","year":"1981","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.1985.01050110038020","article-title":"Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group","volume":"103","year":"1985","journal-title":"Archives of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD008721.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group","volume":"103","year":"1985","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0184|cit184","first-page":"786","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group","volume":"98 Suppl","year":"1991","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0185|cit185","first-page":"823","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group","volume":"98 Suppl","year":"1991","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0186|cit186","first-page":"766","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group","volume":"98 Suppl","year":"1991","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Kassoff","year":"1982","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fphar.2020.00849","article-title":"Anti- vascular endothelial growth factor therapy as an alternative or adjunct to pan-retinal photocoagulation in treating proliferative diabetic retinopathy: meta-analysis of randomized trials","volume":"11","author":"Gao","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s001250051539","article-title":"Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes","volume":"43","author":"Gilbert","year":"2000","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0190|cit190","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0191|cit191","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"20","key":"10.1002\/14651858.CD008721.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","article-title":"Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema","volume":"26","author":"Haritoglou","year":"2006","journal-title":"Retina"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.0742-3071.2001.00603.x","article-title":"What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?","volume":"19","author":"Hayward","year":"2002","journal-title":"Diabetic Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","article-title":"Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs","volume":"29","author":"Hex","year":"2012","journal-title":"Diabetic medicine"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0196|cit196","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jamaophthalmol.2017.0837","article-title":"Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy secondary analysis from a diabetic retinopathy clinical research network randomized clinical trial","volume":"135","author":"Hutton","year":"2017","journal-title":"JAMA Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD008721.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1424\u201332","DOI":"10.1001\/jamaophthalmol.2019.4284","article-title":"Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial","volume":"137","author":"Hutton","year":"2019","journal-title":"JAMA Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1984.01040030398010","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years","volume":"102","author":"Klein","year":"1984","journal-title":"Archives of Ophthalmology"},{"issue":"19","key":"10.1002\/14651858.CD008721.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.1988.03410190112033","article-title":"Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy","volume":"260","author":"Klein","year":"1988","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1001\/archinte.1989.00390110033008","article-title":"Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?","volume":"149","author":"Klein","year":"1989","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/diacare.13.1.34","article-title":"Effect of pregnancy on progression of diabetic retinopathy","volume":"13","author":"Klein","year":"1990","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bjo.86.4.365","article-title":"Blood pressure control and diabetic retinopathy","volume":"86","author":"Klein","year":"2002","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0161-6420(02)01074-6","article-title":"The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study","volume":"109","author":"Klein","year":"2002","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"2247\u201354","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1046\/j.1464-5491.2002.00839.x","article-title":"Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes","volume":"19","author":"Kullberg","year":"2002","journal-title":"Diabetes Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","article-title":"Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study","volume":"121","author":"Li","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/02713683.2017.1379542","article-title":"One-year outcome of conbercept therapy for diabetic macular edema","volume":"43","author":"Li","year":"2018","journal-title":"Current Eye Research"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.ophtha.2016.05.037","article-title":"Cost evaluation of panretinal photocoagulation versus Intravitreal ranibizumab for proliferative diabetic retinopathy","volume":"123","author":"Lin","year":"2016","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ophtha.2018.02.038","article-title":"Cost evaluation of early vitrectomy versus panretinal photocoagulation and intravitreal ranibizumab for proliferative diabetic retinopathy","volume":"125","author":"Lin","year":"2018","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0161-6420(02)00975-2","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema","volume":"109","author":"Martidis","year":"2002","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajo.2006.04.058","article-title":"Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy","volume":"142","author":"Nixon","year":"2006","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1464-5491.1995.tb00528.x","article-title":"The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study","volume":"12","author":"Mathiesen","year":"1995","journal-title":"Diabetic Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0161-6420(94)31217-6","article-title":"Ten-years incidence of visual loss in a diabetic population","volume":"101","author":"Moss","year":"1994","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0161-6420(96)30486-7","article-title":"Cigarette smoking and ten-year progression in diabetic retinopathy","volume":"103","author":"Moss","year":"1996","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1165\/ajrcmb.16.4.9115750","article-title":"Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids","volume":"16","author":"Nauck","year":"1997","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.0640","article-title":"Cardiovascular adverse events with intravitreal anti-vascular endothelial growth factor drugs: a systematic review and meta-analysis of randomized clinical trials","volume":"139","author":"Ngo Ntjam","year":"2021","journal-title":"JAMA Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0161-6420(86)33638-8","article-title":"Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema","volume":"93","author":"Olk","year":"1986","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0220|cit220","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","article-title":"Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.","volume":"118","author":"Pearson","year":"2011","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0222|cit222","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0223|cit223","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1167\/iovs.02-1100","article-title":"How sensitive to clinical change are ETDRS logMAR visual acuity measurements?","volume":"44","author":"Rosser","year":"2003","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/bjophthalmol-2019-313997","article-title":"The estimated healthcare cost of diabetic retinopathy in Indonesia and its projection for 2025","volume":"104","author":"Sasongko","year":"2020","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0227|cit227","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","article-title":"A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema","volume":"114","author":"Scott","year":"2007","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.CIR.0000080735.93327.00","article-title":"Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy","volume":"108","author":"Sennlaub","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0420.2007.01067.x","article-title":"Complications in patients after intravitreal injection of bevacizumab","volume":"86","author":"Shima","year":"2008","journal-title":"Acta Ophthalmologica"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0231|cit231","doi-asserted-by":"crossref","unstructured":"Sivaprasad S Hykin P Prevost AT Vasconcelos J Riddell A Ramu J Intravitreal aflibercept compared with pan-retinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT Southampton (UK): NIHR Journals Library 2018 5 5 10.3310\/eme05050","DOI":"10.3310\/eme05050"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0232|cit232","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008214.pub3","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","author":"Smith","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0233|cit233","first-page":"CD005139","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","journal-title":"Lancet Global Health"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"issue":"9131","key":"10.1002\/14651858.CD008721.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"7160","key":"10.1002\/14651858.CD008721.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/diacare.25.8.1320","article-title":"Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study","volume":"25","author":"Van Leiden","year":"2002","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archopht.121.2.245","article-title":"Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study","volume":"121","author":"Van Leiden","year":"2003","journal-title":"Archives of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub3-BIB0241|cit241","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub5","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","author":"Virgili","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ajo.2016.09.029","article-title":"Outcomes with as-needed aflibercept and macular laser following the phase III VISTA DME Trial: ENDURANCE 12-month extension study","volume":"173","author":"Wykoff","year":"2017","journal-title":"American Journal Ophthalmology"},{"issue":"10326","key":"10.1002\/14651858.CD008721.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12886-017-0554-8","article-title":"Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study","volume":"17","author":"Xu","year":"2017","journal-title":"BMC Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.ophtha.2018.02.019","article-title":"Cost evaluation of laser versus intravitreal aflibercept for proliferative diabetic retinopathy","volume":"125","author":"Yannuzzi","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jcjo.2021.01.017","article-title":"Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis","volume":"56","author":"Yates","year":"2021","journal-title":"Canadian Journal Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub3-BIB0249|cit249","doi-asserted-by":"publisher","first-page":"807687","DOI":"10.3389\/fendo.2022.807687","article-title":"Effectiveness of panretinal photocoagulation plus intravitreal anti-VEGF treatment Aagainst PRP alone for diabetic retinopathy: A systematic review with meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Frontiers in Endocrinology"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub3-BIB0250|cit250","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008721","article-title":"Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Protocol)","author":"Martinez-Zapata","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub3-BIB0251|cit251","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008721.pub2","article-title":"Anti-vascular endothelial growth factor for proliferative diabetic retinopathy","author":"Martinez-Zapata","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:19:56Z","timestamp":1750385996000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008721.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":251,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008721.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]}}}